SCHEMBL3393324

SCHEMBL3393324

Cc1ccc(S(=O)(=O)N2CCc3cc(OCc4ccccc4)ccc3[C@H](O)[C@@H]2C)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 5/20 0.70
MMP2 P08253 4/20 0.70
MMP9 P14780 4/20 0.70
MMP12 P39900 4/20 0.70
MMP14 P50281 4/20 0.70
MMP15 P51511 4/20 0.70
MMP16 P51512 4/20 0.70
MMP7 P09237 3/20 0.70
MMP26 Q9NRE1 3/20 0.70
GRIN1 Q05586 6/20 0.49
GRIN2B Q13224 6/20 0.49
ESR1 P03372 1/20 0.48
ESR2 Q92731 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ADAM17 P78536 3/20 0.47
CD4 P01730 2/20 0.47
MMP13 P45452 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
TAS2R14 Q9NYV8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394741 1.00 MMP1 (0.70) MMP1MMP2MMP9MMP12MMP14
SCHEMBL3392159 1.00 MMP1 (0.70) MMP1MMP2MMP9MMP12MMP14
SCHEMBL3397104 1.00 MMP1 (0.70) MMP1MMP2MMP9MMP12MMP14
SCHEMBL7889207 0.84 MEN1 (0.59) MMP1MMP2MMP9MMP12MMP14
SCHEMBL18587613 0.82 MMP1 (0.52) MMP1MMP2MMP9MMP12MMP14
SCHEMBL18587397 0.82 MMP1 (0.52) MMP1MMP2MMP9MMP12MMP14
SCHEMBL7886910 0.82 MMP1 (0.64) MMP1MMP2MMP9MMP12MMP14
SCHEMBL3392249 0.80 MMP1 (0.61) MMP1MMP2MMP9MMP12MMP14
SCHEMBL3396630 0.80 MMP1 (0.61) MMP1MMP2MMP9MMP12MMP14
SCHEMBL3392244 0.80 MMP1 (0.61) MMP1MMP2MMP9MMP12MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) 2018-09-06 US disclosed
EP-2246331-A1 NR2B-selective NMDA-receptor antagonists Westfälische Wilhelms-Universität Münster (DE) 2010-11-03 EP disclosed
EP-2246331-A1 NR2B-selective NMDA-receptor antagonists Westfälische Wilhelms-Universität Münster (DE) 2010-11-03 EP disclosed
WO-2010122134-A1 NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS Westfälische Wilhelms Universität Münster (DE) 2010-10-28 WO disclosed
WO-2010122134-A1 NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS Westfälische Wilhelms Universität Münster (DE) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES GRIN1, GRIN2B, GRIN3B MMP1 4491/4885MMP2 4755/4885MMP9 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.